两名患者使用利妥昔单抗成功治疗特发性视网膜血管炎。
Successful treatment of idiopathic retinal vasculitis with rituximab in two patients.
作者信息
Apivatthakakul Atitaya, Liu Renee, Sobrin Lucia
机构信息
Department of Ophthalmology, Mass Eye and Ear Infirmary, Harvard Medical School, Boston, MA, USA.
Department of Ophthalmology, Faculty of Medicine, Chiangmai University, Chiangmai, Thailand.
出版信息
Am J Ophthalmol Case Rep. 2023 Apr 12;30:101844. doi: 10.1016/j.ajoc.2023.101844. eCollection 2023 Jun.
PURPOSE
To describe results of treatment of idiopathic retinal vasculitis with intravenous rituximab.
OBSERVATIONS
We present two patients with idiopathic retinal vasculitis who required steroid-sparing therapy and achieved steroid-free remission with intravenous rituximab. Rituximab was used as a first-line steroid-sparing agent after steroids in one patient and as a second-line steroid-sparing agent in the other patient. Both patients achieved steroid-free remission of disease with follow up of at least one year after rituximab initiation.
CONCLUSIONS AND IMPORTANCE
Rituximab achieved steroid-free remission in two patients with idiopathic retinal vasculitis. It should be considered as a treatment option in these patients.
目的
描述静脉注射利妥昔单抗治疗特发性视网膜血管炎的结果。
观察结果
我们报告了两名特发性视网膜血管炎患者，他们需要减用类固醇治疗，并通过静脉注射利妥昔单抗实现了无类固醇缓解。在一名患者中，利妥昔单抗在使用类固醇后作为一线减用类固醇药物，在另一名患者中作为二线减用类固醇药物。两名患者在开始使用利妥昔单抗后至少随访一年均实现了疾病的无类固醇缓解。
结论与意义
利妥昔单抗使两名特发性视网膜血管炎患者实现了无类固醇缓解。在这些患者中应将其视为一种治疗选择。
Zotero 插件